- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 | 391 | GlobeNewswire (Europe) | The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination... ► Artikel lesen | |
| 05.08. | Nuvectis Pharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 05.08. | Nuvectis Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.08. | Nuvectis Pharma GAAP EPS of -$0.30 | 3 | Seeking Alpha | ||
| 05.08. | Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights | 194 | GlobeNewswire (Europe) | NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers... ► Artikel lesen | |
| 04.08. | Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright | 1 | Investing.com | ||
| 31.07. | Nuvectis axes ovarian cancer program after seeing phase 1b data | 2 | FierceBiotech | ||
| NUVECTIS PHARMA Aktie jetzt für 0€ handeln | |||||
| 31.07. | Nuvectis halts NXP800 development for ovarian cancer, shifts focus | 2 | Investing.com | ||
| 31.07. | Nuvectis Pharma, Inc.: Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study | 105 | GlobeNewswire (Europe) | Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases... ► Artikel lesen | |
| 08.07. | Nuvectis reports positive drug interaction study for cancer drug NXP900 | 1 | Investing.com | ||
| 13.06. | Nuvectis Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.05. | Nuvectis Pharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 06.05. | Nuvectis Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.05. | Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights | 109 | GlobeNewswire (Europe) | NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable... ► Artikel lesen | |
| 30.04. | Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 | 1 | Insider Monkey | ||
| 29.04. | Nuvectis Pharma, Inc.: Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting | 1 | GlobeNewswire (USA) | ||
| 26.03. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting | 4 | GlobeNewswire (USA) | ||
| 17.03. | Laidlaw starts Nuvectis Pharma stock with Buy, $19 target | 2 | Investing.com | ||
| 04.03. | Nuvectis meldet vielversprechende Ergebnisse bei Krebstherapie | 4 | Investing.com Deutsch | ||
| 04.03. | Nuvectis reports promising cancer treatment results | 1 | Investing.com |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,960 | -0,24 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Qiagen nach Zahlen von 54 auf 57 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Tycho Peterson attestierte dem... ► Artikel lesen | |
| EVOTEC | 6,356 | -2,37 % | Evotec-Aktie: Kurs heute im Minus (6,566 €) | Die Evotec-Aktie notiert heute etwas leichter. Das Papier kostete zuletzt 6,57 Euro. Heute hat sich an der deutschen Börse die Aktie von Evotec zwischenzeitlich um 3,13 Prozent verbilligt. Der Kurs... ► Artikel lesen | |
| DYNE THERAPEUTICS | 12,380 | -1,12 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,550 | +1,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BOLT PROJECTS | 8,910 | +4,82 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| BIONTECH | 97,00 | -0,05 % | BioNTech einigt sich mit Curevac, GlaxoSmithKline profitiert davon und Novo Nordisk steht zwischen Licht und Schatten | Die Pharmabranche bleibt eine schnelllebige Angelegenheit. Was gestern noch Überflieger war, hat es sich mittlerweile irgendwo im Kurskeller bequem gemacht. In den Augen der Anleger können die Aussichten... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,105 | -0,05 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| VALNEVA | 4,730 | -0,76 % | AKTIE IM FOKUS: Valneva schnellen hoch - Halbjahreszahlen treiben an | PARIS (dpa-AFX) - Robuste Geschäftszahlen zum ersten Halbjahr haben die Aktien von Valneva am Dienstag angetrieben. Die Papiere des französischen Impfstoffherstellers schnellten im frühen Handel um... ► Artikel lesen | |
| IMMUNOME | 10,280 | +3,32 % | Immunome Inc. - 10-Q, Quarterly Report | ||
| ARS PHARMACEUTICALS | 14,540 | +0,48 % | ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales | ||
| RECURSION PHARMACEUTICALS | 5,765 | +2,22 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,690 | +0,91 % | Summit Therapeutics: Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 | Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 4,520 | +1,80 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously... ► Artikel lesen | |
| LENZ THERAPEUTICS | 37,870 | -7,43 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 6,820 | +3,33 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen |
Das Unternehmen NUVECTIS PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,010 (+0,16 %) liegt der Kurs bei 6,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NUVECTIS PHARMA INC finden Sie auf Wallstreet Online.